Internal Medicine, Endocrinology, Diabetes, & Metabolism · La Follette, TN
NPI
1396940656
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
130 Independence Ln
La Follette, TN, 37766
Phone (423) 562-1705
Groups this clinician bills Medicare through
Medicare paid, 2024
$3,314
3,070 services
Medicare patients, 2024
49
Average age 68
Drug cost, 2024
$2.4M
4,454 prescriptions
Company payments, 2025
$16K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Safwan Hamwi was code 82948 (clinical chemistry), 136 times for 48 patients. In total Safwan Hamwi billed 3,070 services in 8 codes, and Medicare paid $3,314.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 82948 Clinical Chemistry | Office | 136 | 48 | $4.71 | $641 |
| 83036 Blood Count | Office | 110 | 46 | $9.21 | $1,013 |
By year: 2022 $2,570 for 2,669 services; 2023 $3,449 for 2,488 services; 2024 $3,314 for 3,070 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82948 Clinical Chemistry | 136 | 48 | $4.71 | $641 |
| 83036 Blood Count | 110 | 46 | $9.21 | $1,013 |
Medicare prescription drug claims, 2024
In 2024, the drug Safwan Hamwi prescribed most often to Medicare patients was Levothyroxine Sodium, with 780 prescriptions and refills. In total Safwan Hamwi wrote 4,454 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 780 | 1,470 | 178 | $4,702 |
| Mounjaro Tirzepatide | 464 | 526 | 60 | $555K |
| Humalog Insulin Lispro | 263 | 316 | 49 | $65K |
| Ozempic Semaglutide | 217 | 245 | 40 | $225K |
| Jardiance Empagliflozin | 183 | 222 | 28 | $132K |
| Insulin Lispro Generic | 152 | 193 | 34 | $15K |
| Tradjenta Linagliptin | 134 | 164 | 21 | $84K |
| Novolog Insulin Aspart | 129 | 173 | 29 | $36K |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 120 | 182 | 21 | $167K |
| Metformin Hcl Generic | 100 | 182 | 19 | $445 |
| Glimepiride Generic | 96 | 191 | 20 | $540 |
| Glyxambi Empagliflozin/Linagliptin | 82 | 92 | Under 11 | $57K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 77 | 118 | 20 | $9,695 |
| Methimazole Generic | 77 | 162 | 21 | $531 |
| Kerendia Finerenone | 75 | 97 | 12 | $63K |
Brand drugs: 2,743 claims; generic drugs: 1,112 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Safwan Hamwi $16K ($16K in general payments such as food, travel and fees) from 16 companies. The largest payer was CeQur Corporation with $7,178.
| Company | Payments | Amount |
|---|---|---|
| CeQur Corporation | 3 | $7,178 |
| Xeris Pharmaceuticals, Inc. | 36 | $6,319 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $1,205 |
| Corcept Therapeutics CORT | 24 | $563 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 14 | $327 |
| Medtronic, Inc. MDT | 10 | $239 |
| Sequel Med Tech, LLC | 5 | $207 |
| Mannkind Corporation MNKD | 5 | $125 |
| Amphastar Pharmaceuticals, Inc. AMPH | 4 | $61.67 |
| Abbott Laboratories ABT | 3 | $57.13 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.